Absynth Biologics Ltd

Information

Development of anti-bacterial vaccines and antibodies. The investment will be used by Absynth to advance its Staphyloccus aureus vaccine programme to key pre-clinical milestones. The investment will also complement funding secured from TSB Biomedical Catalyst scheme to further develop Absynth’s product pipeline to prevent Clostridium difficile and Steptococcus pyogenes infections.